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Introduction: Afatinib, an oral irreversible ErbB Family Blocker, 
has demonstrated efficacy and safety in epidermal growth factor 
receptor (EGFR) mutation-positive advanced lung adenocarcinoma. 
It is unknown whether such activity also occurs in patients with 
EGFR gene overexpression, regardless of mutation status. This phase 
II study investigated the activity and safety of afatinib in advanced 
non–small-cell lung cancer with increased EGFR gene copy num-
ber and/or gene amplification by fluorescence in situ hybridization 
(FISH), with or without EGFR mutation.
Methods: EGFR gene overexpression was assessed by FISH analy-
sis; patients with high polysomy or gene amplification were consid-
ered FISH positive. Patients received daily afatinib less than or equal 
to 50 mg (monotherapy). Endpoints included objective response rate 
(ORR; primary), disease control rate (DCR), progression-free sur-
vival (PFS), overall survival (OS), and safety.
Results: Of 223 patients screened, 69 patients were FISH-positive 
and met eligibility criteria for treatment. The ORR was 13.0% over-
all (n = 9 of 69). Higher ORRs were observed in patients with gene 
amplification (20.0%; n = 5 of 25) and EGFR mutation-positive 
tumors (25.0%; n = 3 of 12). The DCR was 50.7% overall (n = 35 
of 69; median duration: 24.9 weeks) with higher DCRs observed 
in patients with gene amplification 64.0%; (n = 16 of 25), and in 
patients with EGFR mutation-positive tumors 66.7% (n = 8 of 12). 
In the overall population, median PFS was 8.4 weeks and median OS 
was 50.4 weeks. The most common afatinib-related adverse events 
were rash/acne (83%) and diarrhea (78%).
Conclusions: First- or second-line afatinib demonstrated prelimi-
nary activity and manageable safety in EGFR FISH-positive patients 
with advanced non–small-cell lung cancer.
Key Words: Afatinib, EGFR FISH-positive, ErbB family, Non–
small-cell lung cancer.
(J Thorac Oncol. 2015;10: 665–672)
The ErbB family comprises epidermal growth factor recep-tor (EGFR; ErbB1), human EGFR (HER2; ErbB2), ErbB3 
and ErbB4, transmembrane receptors with roles in the trans-
mission of extracellular growth signals. Erlotinib and gefi-
tinib, reversible EGFR tyrosine-kinase inhibitors (TKIs), are 
established as first-line therapy for patients with non–small-
cell lung cancer (NSCLC) harboring EGFR mutations and are 
associated with initial response rates of 55–83% and progres-
sion-free survival (PFS) of approximately 9–13 months.1–7 
However, EGFR gene overexpression, identified by fluores-
cence in situ hybridization (FISH), may also be associated 
with response to EGFR-TKIs irrespective of EGFR mutation 
status.8 Indeed, an analysis of previous trials shows that EGFR 
FISH-positive status may be a good predictor of response to 
erlotinib and gefitinib therapy in lung cancers.9
Afatinib is an orally available, irreversible ErbB fam-
ily blocker that selectively and potently blocks signaling from 
all relevant ErbB family receptors (EGFR/ErbB1, HER2/
ErbB2, and ErbB4) and trans-phosphorylation of ErbB3.10,11 
ErbB family signaling is initiated by ligand-induced homo- 
and heterodimerization;12,13 thus blockade of ErbB family 
signaling potentially offers improved efficacy over inhibition 
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of EGFR alone and may also prevent resistance mediated by 
compensatory signaling.11 Afatinib has demonstrated first-line 
efficacy versus chemotherapy in two large phase III trials14,15 
conducted in patients with EGFR mutation-positive advanced 
lung adenocarcinoma. However, afatinib has not been specifi-
cally evaluated in patients with NSCLC, who have EGFR gene 
overexpression, regardless of mutation status, a population that 
may potentially derive benefit from its mechanistic profile of 
irreversible inhibition of all ErbB family receptors. This study 
was thus designed to evaluate the efficacy and safety of afa-
tinib in patients with EGFR gene overexpression (high poly-
somy and amplification) as determined by FISH and with no 
prior EGFR-TKI therapy in the first- and second-line settings.
PATIENTS AND METHODS
Patients
The study recruited patients aged greater than or equal to 
18 years with pathologically confirmed stage IIIB/IV NSCLC 
with EGFR FISH-positive disease (defined as high EGFR 
gene copy number [polysomy] and/or gene amplification). All 
patients had at least one tumor lesion which would meet the cri-
teria for “measurable lesion” according to Response Evaluation 
Criteria In Solid Tumors (RECIST) 1.0 criteria,16 i.e., that could 
be measured by computed tomography (CT) or magnetic reso-
nance imaging (MRI) in at least one dimension, with the lon-
gest diameter to be recorded as greater than or equal to 20 mm 
using conventional techniques (CT/MRI) or greater than or 
equal to 10 mm with spiral CT scan. All patients had an Eastern 
Cooperative Oncology Group (ECOG) performance status of 
0–2 and a life expectancy of at least 3 months. Patients were 
excluded if they had undergone more than two prior cytotoxic 
chemotherapy regimens for NSCLC (including adjuvant che-
motherapy if relapse occurred less than 12 months previously), 
prior treatment with any EGFR-inhibiting small molecule or 
antibody, and either radiotherapy within the past 2 weeks or 
chemotherapy within the past 4 weeks before first drug admin-
istration. Patients with active brain metastases (stable less than 4 
weeks, symptomatic, requiring treatment with anticonvulsants, 
or leptomeningeal disease), pre-existing interstitial lung dis-
ease, acute gastrointestinal disorders with diarrhea as a major 
symptom, or organ system dysfunction were also excluded.
Study Design
This was a phase II, open-label, single-arm, clinical trial 
conducted in 10 centers in Italy. The primary endpoint was con-
firmed objective response as assessed using RECIST version 1.0. 
Baseline tumor assessments were performed within 28 days before 
the start of study treatment. Postbaseline tumor assessments were 
performed at weeks 8 and 16, and every 8 weeks thereafter.
Secondary endpoints included disease control, PFS, 
overall survival (OS), and safety. Disease control was defined 
as the best response of complete response (CR), partial 
response (PR), or stable disease (SD). PFS time was defined as 
the time from start of treatment until the occurrence of disease 
progression or death, whichever occurred first. OS time was 
defined as the number of days from the date of start of treat-
ment to the date of death. The safety of afatinib was assessed 
in terms of intensity and incidence of AEs, especially skin 
reactions and gastrointestinal AEs (according to Common 
Terminology Criteria for Adverse Events version 3.0).
Treatment
Afatinib 50 mg once daily was administered continuously 
in 28-day cycles until tumor progression (progressive disease 
according to RECIST1.0) or intolerable AEs. In the event of 
prespecified drug-related AEs, dose reductions to 40 mg per 
day, and then to 30 mg per day, were allowed. Any further AEs 
led to termination of afatinib and withdrawal from the study.
Molecular Testing
Molecular testing of biopsies was carried out by an inde-
pendent central laboratory (Centro Studi sull’invecchiamento, 
Chieti, Italy). Kirsten rat sarcoma viral oncogene homolog (KRAS) 
and EGFR mutation testing was performed using commercially 
available kits (KRAS: Therascreen Kras Pyro kit, Qiagen, Hilden, 
Germany; EGFR: Vysis EGFR/CEP 7 FISH Probe Kit, Abbott 
Molecular, North Chicago, IL). Increased EGFR gene copy num-
ber was assessed by standard FISH analysis. EGFR gene copy 
number and chromosome 7 number were assessed in at least 50 
nonoverlapping nuclei with intact morphology. Patients were 
considered to be FISH-positive if they displayed high polysomy 
(greater than or equal to four copies of the EGFR gene in greater 
than or equal to 40% of cells) or gene amplification, defined by 
the presence of tight EGFR gene clusters and a gene/chromo-
some per cell ratio of at least 2, or an average of greater than or 
equal to 15 copies of EGFR per cell in greater than or equal to 
10% of analyzed cells. Only patients with high polysomy or gene 
amplification were considered to be FISH-positive.
Statistical Analysis
All statistical analyses were descriptive and exploratory; 
no formal statistical inferences were planned or performed. 
Assuming an underlying response rate of 75%, greater than 
or equal to 30 patients was determined to be the smallest 
sample size that would provide 80% probability that the 90% 
lower confidence interval (CI) of the objective response rate 
(ORR) would be greater than 50%. Safety and efficacy analy-
ses were conducted in the treated population. Kaplan–Meier 
estimates and 95% CIs (using Greenwood’s standard error 
estimate) were tabulated at planned imaging intervals for PFS 
and OS. The ORR was analyzed in predefined patient sub-
groups: baseline FISH category (high polysomy versus gene 
amplification); baseline KRAS and EGFR mutational status; 
baseline ECOG performance status (0, 1 versus 2); gender 
and smoking history. For 10 patients, both FISH categories 
(high polysomy and gene amplification) were documented; to 
distinguish the results for these patients from those in the indi-
vidual high polysomy and gene amplification groups a sepa-
rate category of high polysomy/gene amplification was used.
Ethics
The study was conducted in accordance with the 
Declaration of Helsinki and guidelines on Good Clinical 
Practice, and the protocol was approved by a local ethics com-
mittee at each participating center. All patients provided written 
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informed consent to participate. This study is registered with 
ClinicalTrials.gov (NCT00796549).
RESULTS
Patient Characteristics and Disposition
Between December 2008 and September 2011, 223 
patients were screened and 69 eligible FISH-positive patients 
entered the study and received study treatment. Patient demo-
graphics and oncologic history are summarized in Table 1. At 
the time of the primary analysis, treatment had been discontin-
ued in 66 patients (95.7%), because of progressive disease in 53 
patients (76.8%), AEs in 11 patients (15.9%) or other reasons 
in 2 patients (2.9%; reasons: medical decision based on gen-
eral condition of the patient, n = 1; medical opinion that patient 
needed treatment with a different therapy, n = 1); three patients 
were continuing on treatment. The median treatment duration 
with afatinib was 8.1 weeks. Initial dose reduction to afatinib 
40 mg occurred in 31 patients because of AEs; 15 of these 
patients then underwent a second reduction to afatinib 30 mg.
Tumor Response
Sixty-one patients were evaluable for response; eight 
patients discontinued from study treatment without on-treat-
ment follow-up RECIST assessment. All patients were FISH-
positive and in this overall population, nine patients (13.0%) 
achieved a confirmed objective response, including 1 CR 
(Table 2), with a median duration of response of 31.4 weeks 
(range: 11.6–115.7 weeks). CR was achieved by a patient 
whose tumor had EGFR gene amplification and unknown 
EGFR mutation status. Confirmed response rate was 15.0% (6 
of 40 patients) for first-line and 10.3% (3 of 29) for second-
line patients in the overall population. Responses in various 
patient subgroups are listed in Table 3. Patients with EGFR 
gene amplification had an ORR of 20.0% (5 of 25); among 
those with EGFR high polysomy ORR was 8.8% (3 of 34), 
whereas patients with EGFR high polysomy/gene amplifica-
tion achieved an ORR of 10.0% (1 of 10). In patients with 
known EGFR mutation status (55 of 69, 80%), ORRs were 
TABLE 1.  Patient Disposition and Demographic Data
Overall 
Population
EGFR FISH Status
Gene 
Amplification
High 
Polysomy
Gene Amplification/ 
High Polysomy
Total number of patients treated, n (%) 69 (100.0) 25 (100.0) 34 (100.00) 10 (100.0)
EGFR mutation status, n (%)
  Negative 43 (62.3) 16 (64.0) 19 (55.9) 8 (80.0)
  Positive 12 (17.4) 3 (12.0) 8 (23.5) 1 (10.0)
  Unknown 14 (20.3) 6 (24.0) 7 (20.6) 1 (10.0)
Male:female, n (%) 35 (50.7):34 (49.3) 15 (60.0):10 (40.0) 15 (44.1):19 (55.9) 5 (50.0):5 (50.0)
Mean (SD) age, years 64 (11) 63 (12) 65 (11) 65 (11)
Smoking status
  Never smoker 21 (30.4) 8 (32.0) 9 (26.5) 4 (40.0)
  Ex-smoker 41 (59.4) 14 (56.0) 21 (61.8) 6 (60.0)
  Current smoker 7 (10.1) 3 (12.0) 4 (11.8) 0 (0)
Histologic classification, n (%)
  Adenocarcinoma 61 (88.4) 24 (96.0) 28 (82.4) 9 (90.0)
  Bronchoalveolar 3 (4.3) 1 (4.0) 2 (5.9) 0 (0)
  Squamous 5 (7.2) 0 (0) 4 (11.8) 1 (10.0)
Prior lines of therapy, n (%)
  0 40 (58.0) 14 (56.0) 19 (55.9) 7 (70.0)
  1 29 (42.0) 11 (44.0) 15 (44.1) 3 (30.0)
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization.
TABLE 2.  Best Overall Response to Treatment: All Patients
Afatinib 50 mg
n (%) 95% CI
Patients 69 (100.0)
Disease control 35 (50.7) 38.4, 63.0
  Objective response 9 (13.0) 6.1, 23.3
   Complete response 1 (1.4) 0.0, 7.8
   Partial response 8 (11.6) 5.1, 21.6
  Stable disease 26 (37.7) 26.3, 50.2
   Stable disease 22 (31.9)
   Unconfirmed objective response 4 (5.8)
Progressive disease 26 (37.7) 26.3, 50.2
Unknown (not assessable, insufficient data) 8 (11.6)
  Clinical progression 4 (5.8)
  Death 3 (4.3)
  Progression during follow-upa 1 (1.4)
aThis patient entered the follow-up phase without being in progression (trial 
treatment was interrupted for other reasons), and then progressed during the follow-up 
phase; progressive disease was not assessed via Response Evaluation Criteria in Solid 
Tumors during follow-up.
CI, Clopper-Pearson exact confidence interval.
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25.0% (3 of 12) for EGFR mutation-positive tumors and 9.3% 
(4 of 43) for EGFR wild-type tumors. In patients with known 
KRAS mutation status, ORRs were 15.8% (6 of 38 patients) 
in patients with KRAS wild-type tumors and 0% (0 of 10) in 
those with KRAS mutation-positive tumors. ORR was 23.5% in 
female patients (8 of 34) and 28.6% (6 of 21) in never-smokers.
Overall, 50.7% of patients (35 of 69) achieved disease 
control (Table 2); median duration of disease control was 
24.9 weeks (range: 7.7–165.7 weeks). Disease control rates 
(DCRs) in patient subgroups are listed in Table 3. In patients 
with EGFR gene amplification, EGFR high polysomy and 
high polysomy/gene amplification DCRs were 64.0% (16 of 
25 patients), 44.1% (15 of 34), and 40.0% (4 of 10), respec-
tively (Table 3). For patients with known EGFR mutation 
status, DCRs of 66.7% (8 of 12) and 46.5% (20 of 43) were 
achieved in patients with EGFR mutation-positive and EGFR 
wild-type tumors, respectively. DCR in female patients was 
61.8% (21 of 34) and was 81.0% (17 of 21) in never-smok-
ers. Sixty patients had evaluable target lesion measurements 
by RECIST. The mean maximum decrease from baseline in 
the sum of the longest diameter of target lesions was -5.9% 
(standard deviation 31.6%). Changes in tumor size for each 
evaluable patient are shown in Figure 1A.
The best confirmed tumor response among five patients 
with squamous histology was SD in four patients. These four 
cases of SD were of 23–71 weeks duration and included one 
unconfirmed PR (-33.3% reduction in tumor lesion size) and two 
minor responses, not qualifying for PR by RECIST (-29.7% and 
-23.1% reduction in the size of target lesions). One patient with 
squamous cell carcinoma had progressive disease.
Progression-Free and Overall Survival
In the overall population, median PFS was 8.4 weeks 
(95% CI: 7.4–15.7; Table 4, Supplementary Figure 1, SDC, 
http://links.lww.com/JTO/A751). Median PFS was 15.6 
weeks in patients with EGFR gene amplification, 7.9 weeks 
in patients with EGFR high polysomy and 8.1 weeks in those 
with EGFR high polysomy/gene amplification. For patients 
with known EGFR mutation status, median PFS was 22.2 
weeks in patients with EGFR mutation-positive tumors and 
TABLE 3.  Objective Response and Disease Control Rate in the Subgroups
Patients n
Afatinib 50 mg
Objective Response 
rate, n (%) 95% CI
Disease Control 
Rate, n (%) 95% CI
All 69 9 (13.0) 6.1, 23.3 35 (50.7) 38.4, 63.0
Gender
  Male 35 1 (2.9) 0.1, 14.9 14 (40.0) 23.9, 57.9
  Female 34 8 (23.5) 10.7, 41.2 21 (61.8) 43.6, 77.8
Smoking status
  Never smoker 21 6 (28.6) 11.3, 52.2 17 (81.0) 58.1, 94.6
  Ex-smoker 41 3 (7.3) 1.5, 19.9 15 (36.6) 22.1, 53.1
  Current smoker 7 0 (0.0) 0, 41.0 3 (42.9) 9.9, 81.6
Line of treatment in the study
  First line 40 6 (15.0) 5.7, 29.8 20 (50.0) 33.8, 66.2
  Second line 29 3 (10.3) 2.2, 27.4 15 (51.7) 32.5, 70.6
ECOG PS
  0 33 6 (18.2) 7.0, 35.5 21 (63.6) 45.1, 79.6
  1 35 3 (8.6) 1.8, 23.1 14 (40.0) 23.9, 57.9
  2 1 0 (0.0) 0, 97.5 0 (0.0) 0, 97.5
FISH status
  High polysomy 34 3 (8.8) 1.9, 23.7 15 (44.1) 27.2, 62.1
  Gene amplification 25 5 (20.0) 6.8, 40.7 16 (64.0) 42.5, 82.0
  High polysomy/gene amplification 10 1 (10.0) 0.3, 44.5 4 (40.0) 12.2, 73.8
EGFR mutation status
  Negative 43 4 (9.3) 2.6, 22.1 20 (46.5) 31.2, 62.3
  Positive 12 3 (25.0) 5.5, 57.2 8 (66.7) 34.9, 90.1
  Unknown 14 2 (14.3) 1.8, 42.8 7 (50.0) 23.0, 77.0
KRAS mutation status
  Negative 38 6 (15.8) 6.0, 31.3 18 (47.4) 31.0, 64.2
  Positive 10 0 (0.0) 0, 30.8 3 (30.0) 6.7, 65.2
  Not evaluable 14 1 (7.1) 0.2, 33.9 8 (57.1) 28.9, 82.3
CI, Clopper-Pearson exact confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; FISH, fluorescence 
in situ hybridization.
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7.9 weeks in those with EGFR wild-type tumors. For patients 
with known KRAS mutation status, PFS was 7.7 weeks in 
those with KRAS mutation-positive tumors and 8.1 weeks in 
those with KRAS wild-type tumors. PFS in individual patients 
is shown in Figures 1A and B.
Fifty-three patients (76.8%) had died at the time of the 
primary analysis. In the overall population, median OS was 
50.4 weeks (95% CI: 33.4–64.0; Table 4, Supplementary 
Figure 1, SDC, http://links.lww.com/JTO/A751), median OS 
was 60.4 weeks in patients with EGFR gene amplification; 
67.7 weeks in those with EGFR high polysomy/gene amplifi-
cation and 37.8 weeks in patients with EGFR high polysomy 
alone. Median OS was 72.4 weeks in patients with EGFR 
mutation-positive tumors and 51.9 weeks in patients with 
EGFR wild-type tumors. In patients with KRAS mutation-
positive NSCLC, median OS was 54.3 weeks; for those with 
KRAS wild-type NSCLC, median OS was 39.4 weeks.
Safety
Drug-related AEs were reported in 64 out of 69 treated 
patients (92.8%), the most frequently occurring were rash/acne 
(82.6%), diarrhea (78.3%), and stomatitis (37.7%; Table 5). 
Treatment discontinuations due to AEs occurred in 24 patients 
(34.8%). The most common AEs leading to discontinuation 
were diarrhea (7.2%) and rash/acne (7.2%); in four patients 
(5.8%) the AEs were disease-related. Overall, 13 patients 
(18.8%) experienced AEs that led to the patient’s death. None 
of the AEs leading to death were considered to be drug-related.
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0
–20
–40
–60
–80
–100 Patients
M
ax
im
um
 c
ha
ng
e 
fr
om
 b
as
el
in
e 
in
 tu
m
ou
r s
iz
e 
(%
)
100
80
60
40
20
180
160
140
120
0
100
80
60
40
20
P
F
S
  (w
eeks)
A
B
FIGURE 1. A, Waterfall plot showing maximum per-
cent change from baseline in size of tumors, PFS and 
EGFR mutation status in response-evaluable patients; 
and B, PFS in all patients according to gene amplifica-
tion/polysomy status, histology and EGFR mutational 
status. EGFR+, EGFR mutation-positive; bars not indi-
cated as EGFR+ or asterisk, EGFR wild-type.
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DISCUSSION
This study assessed the efficacy and safety of afatinib 
in patients whose tumors exhibited EGFR gene overexpres-
sion as determined by FISH-positivity criteria (high polysomy 
and/or gene amplification); the majority of patients (62%) 
were known to have EGFR wild-type tumors. In this heterog-
enous patient population, overall ORR was 13.0% and DCR 
was 50.7%. Response rates in patients with EGFR mutation-
positive tumors were higher than those observed in patients 
with EGFR wild-type tumors (25.0% versus 9.3%), but were 
lower than expected given that response rates in previous trials 
with afatinib in patients with EGFR mutation-positive disease 
have been above 50%.14,15,17 However, our study enrolled only 
12 patients known to have EGFR-mutant disease, thus small 
differences have a large impact on the percentages reported, 
and we cannot exclude that by chance we selected a consistent 
proportion of resistant cases. Another factor that may be 
relevant is the fact that seven of the 12 patients with EGFR-
positive disease did not have details of the specific mutation 
available, and it is possible that these patients had uncom-
mon mutations, which are less responsive to EGFR-TKIs and 
would drive the response rate down. As expected, the AE pro-
file observed was in line with previous trial experience.14,15,17–20 
Interestingly, noteworthy clinical activity was observed in 
patients with FISH-positive EGFR wild-type tumors, a popu-
lation for whom afatinib is not currently indicated.21,22
The results reported here suggest that a further popula-
tion of patients represent an identifiable subgroup that may 
benefit from afatinib therapy. Given the varying concordance 
between FISH-positivity and EGFR-mutation positivity in 
the current study (only 22% of patients with known mutation 
status were EGFR mutation-positive) and other studies,23,24 it 
may be advantageous to test patients for both EGFR mutation 
and FISH-positivity to guide treatment decisions.
Previous reports have indicated that the genetic abnor-
malities detected by FISH are of differing biological sig-
nificance,25,26 and, consistent with this hypothesis, median 
survival times (PFS and OS) in the current study were numeri-
cally longer in patients with gene amplification than in those 
with high polysomy. The hypothesis that EGFR wild-type 
FISH-positive patients may represent an additional popula-
tion of NSCLC patients who could benefit from EGFR-TKIs 
is supported by other studies. In a retrospective study of 247 
patients with EGFR wild-type tumors treated with gefitinib or 
erlotinib, PFS was significantly longer in FISH-positive than 
in FISH-negative patients.27 Further clinical studies, includ-
ing ISEL and ONCOBEL, have also identified a correlation 
between FISH-positivity and improved efficacy outcomes 
(response rate, PFS, OS) to EGFR-TKIs.23,28,29 However, a 
number of other studies have failed to detect a significant 
relation between FISH-positivity and improved outcomes.30,31 
This lack of overall correlation could potentially be explained 
TABLE 4.  Progression-Free Survival and Overall Survival by 
Subgroup
Afatinib 50 mg
Patients, n
Progression-Free 
Survival, Weeks 
(Median,  
95% CI)
Overall  
Survival, Weeks  
(Median,  
95% CI)
All 69 8.4 (7.4–15.7) 50.4 (33.4–64.0)
Gender
  Male 35 7.6 (7.0–9.4) 43.3 (20.4–60.4)
  Female 34 21.3 (7.9–27.0) 57.2 (37.1–105.9)
Smoking status
  Never smoker 21 24.9 (9.4–46.9) 95.6 (37.1–NE)
  Ex-smoker 41 7.9 (7.0–10.0) 38.4 (20.4–51.9)
  Current smoker 7 7.3 (5.0–15.1) 54.3 (7.4–78.9)
Line of therapy in the study
  First line 40 8.4 (7.6–16.1) 64.0 (26.9–105.9)
  Second line 29 12.1 (6.7–23.1) 38.4 (21.6–54.3)
ECOG PS
  0 33 15.7 (7.7–33.0) 83.9 (54.3–105.9)
  1 35 8.0 (6.9–12.1) 26.9 (16.0–42.3)
  2 1 3.3 (NE–NE) 3.3 (NE–NE)
FISH status
  High polysomy 34 7.9 (7.1–16.1) 37.8 (20.9–60.0)
  Gene amplification 25 15.6 (7.0–33.0) 60.4 (30.6–95.6)
  High polysomy/gene 
amplification
10 8.1 (5.0–15.7) 67.7 (16.0–NE)
EGFR mutation status
  Negative 43 7.9 (7.3–12.1) 51. 9 (33.0–75.7)
  Positive 12 22.2 (5.4–38.3) 72.4 (14.9–NE)
  Unknown 14 11.6 (5.0–46.6) 25.9 (8.9–105.9)
KRAS mutation status
  Negative 38 8.1 (7.1–15.7) 54.3 (38.4–75.7)
  Positive 10 7.7 (1.7–8.3) 39.4 (1.7–83.9)
  Not evaluable 14 15.5 (6.9–27.0) 30.3 (14.9–90.4)
CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group 
performance status; EGFR, epidermal growth factor receptor; FISH, fluorescence in situ 
hybridization; NE, nonestimable.
TABLE 5.  Drug-Related Adverse Events (>10%) by Grade
All Grades
n (%)
Grade 3
n (%)
Grade 4
n (%)
Patients with drug- 
related AEs
64 (92.8) 28 (40.6) 2 (2.9)
Rash/acnea 57 (82.6) 19 (27.5) -
Diarrhea 54 (78.3) 7 (10.1) 2 (2.9)
Stomatitisa 26 (37.7) 4 (5.8) -
Fatiguea 14 (20.3) 3 (4.3) -
Nail effecta 11 (15.9) 1 (1.4) -
Dry skin 10 (14.5) - -
Decreased appetite 9 (13.0) 1 (1.4) -
Pruritus 9 (13.0) - -
Nausea 8 (11.6) - -
Ocular effecta 8 (11.6) - -
Vomiting 7 (10.1) - -
No drug-related AEs of grade 5 were observed.
aGrouped terms.
AE, adverse event.
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by regional intratumor differences in EGFR copy number32 
and differences in study design. For example, use of an active 
agent as a comparator, as was the case in the INTEREST 
study, may mask any additional survival benefit conferred by 
EGFR high gene copy number.30
Treatment options for patients with tumors of squa-
mous histology, which is not typically associated with EGFR-
sensitizing mutations,33 are limited and there is a particular need 
for effective therapies for these patients. Indeed, all five of the 
patients with squamous histology tumors in this study were 
EGFR wild-type. However, disease control with afatinib was 
observed in four of these five. This observation supports other 
studies that suggest FISH-positivity may identify patients with 
squamous cell lung cancer who may benefit from EGFR-TKIs. 
For example, in a previous report of 71 patients with advanced 
squamous cell lung cancer, EGFR FISH-positivity, identified in 
27% of patients, correlated with response to erlotinib or gefitinib 
(p = 0.005).34 These preliminary data suggest that further evalu-
ation of EGFR FISH status in this population may be merited.
Afatinib had a manageable AE profile in patients with 
EGFR gene overexpressed NSCLC; the most commonly 
reported AEs were diarrhea and skin rash, in line with previ-
ous trial experience.17,18 There were no unusual or unexpected 
safety signals in the population of EGFR FISH-positive 
patients with advanced NSCLC; the safety data and AE profile 
of afatinib in this study were consistent with previous studies 
investigating a dose of afatinib 50 mg.
In conclusion, afatinib demonstrated preliminary activ-
ity and a generally manageable safety profile in EGFR FISH-
positive patients with advanced NSCLC. The disease control 
observed in patients with FISH-positive EGFR wild-type 
tumors suggests that EGFR FISH testing may identify an 
additional subset of patients with NSCLC who would benefit 
from first- or second-line afatinib therapy and indicate that 
additional investigations of afatinib in EGFR wild-type EGFR 
FISH-positive patients are warranted. Preliminary results in 
patients with squamous cell carcinoma support further inves-
tigation by FISH testing of EGFR as a potential biomarker in 
this patient population.
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